132 related articles for article (PubMed ID: 6691968)
1. Selective inhibition of thrombin by (2R,4R)-4-methyl-1-[N2-[(3-methyl-1,2,3,4-tetrahydro-8-quinolinyl++ +) sulfonyl]-l-arginyl)]-2-piperidinecarboxylic acid.
Kikumoto R; Tamao Y; Tezuka T; Tonomura S; Hara H; Ninomiya K; Hijikata A; Okamoto S
Biochemistry; 1984 Jan; 23(1):85-90. PubMed ID: 6691968
[TBL] [Abstract][Full Text] [Related]
2. Geometry of binding of the benzamidine- and arginine-based inhibitors N alpha-(2-naphthyl-sulphonyl-glycyl)-DL-p-amidinophenylalanyl-pipe ridine (NAPAP) and (2R,4R)-4-methyl-1-[N alpha-(3-methyl-1,2,3,4-tetrahydro-8- quinolinesulphonyl)-L-arginyl]-2-piperidine carboxylic acid (MQPA) to human alpha-thrombin. X-ray crystallographic determination of the NAPAP-trypsin complex and modeling of NAPAP-thrombin and MQPA-thrombin.
Bode W; Turk D; Stürzebecher J
Eur J Biochem; 1990 Oct; 193(1):175-82. PubMed ID: 2226434
[TBL] [Abstract][Full Text] [Related]
3. Similarity and dissimilarity in the stereogeometry of the active sites of thrombin, trypsin, plasmin and glandular kallikrein.
Hijikata-Okunomiya A; Okamoto S; Kikumoto R; Tamao Y; Ohkubo K; Tezuka T; Tonomura S; Matsumoto O
Thromb Res; 1987 Mar; 45(5):451-62. PubMed ID: 2954262
[TBL] [Abstract][Full Text] [Related]
4. Refined 2.3 A X-ray crystal structure of bovine thrombin complexes formed with the benzamidine and arginine-based thrombin inhibitors NAPAP, 4-TAPAP and MQPA. A starting point for improving antithrombotics.
Brandstetter H; Turk D; Hoeffken HW; Grosse D; Stürzebecher J; Martin PD; Edwards BF; Bode W
J Mol Biol; 1992 Aug; 226(4):1085-99. PubMed ID: 1518046
[TBL] [Abstract][Full Text] [Related]
5. Argatroban and inhibition of the vasomotor actions of thrombin.
Winn MJ; Jain K; Ku DD
J Cardiovasc Pharmacol; 1993 Nov; 22(5):754-60. PubMed ID: 7506329
[TBL] [Abstract][Full Text] [Related]
6. Selective inhibition of trypsin by (2R,4R)-4-phenyl-1-[Nalpha-(7- methoxy-2-naphthalenesulfonyl)-L-arginyl]-2-piperidinecarboxylic acid.
Hijikata-Okunomiya A; Tamao Y; Kikumoto R; Okamoto S
J Biol Chem; 2000 Jun; 275(25):18995-9. PubMed ID: 10748093
[TBL] [Abstract][Full Text] [Related]
7. In vitro studies of a new synthetic thrombin inhibitor.
Green D; Ts'ao C; Reynolds N; Kahn D; Kohl H; Cohen I
Thromb Res; 1985 Jan; 37(1):145-53. PubMed ID: 3983896
[TBL] [Abstract][Full Text] [Related]
8. Potent inhibition of thrombin by the newly synthesized arginine derivative No. 805. The importance of stereo-structure of its hydrophobic carboxamide portion.
Okamoto S; Hijikata A; Kikumoto R; Tonomura S; Hara H; Ninomiya K; Maruyama A; Sugano M; Tamao Y
Biochem Biophys Res Commun; 1981 Jul; 101(2):440-6. PubMed ID: 7306088
[No Abstract] [Full Text] [Related]
9. Synthesis of monomeric and polymeric conjugates carrying a thrombin inhibitor through an ester bond.
Noguchi H; Iwata H; Ikada Y
J Biomed Mater Res; 1998 Mar; 39(4):621-9. PubMed ID: 9492224
[TBL] [Abstract][Full Text] [Related]
10. Effect of a selective thrombin inhibitor MCI-9038 on fibrinolysis in vitro and in vivo.
Tamao Y; Yamamoto T; Kikumoto R; Hara H; Itoh J; Hirata T; Mineo K; Okamoto S
Thromb Haemost; 1986 Aug; 56(1):28-34. PubMed ID: 2877508
[TBL] [Abstract][Full Text] [Related]
11. [Antinephritic effect of MD-805 [(2R, 4R) -4-methyl-[N2-(3-methyl-1,2,3,4-tetrahydro-8-quinolinesulfonyl) -L-arginyl] -2-piperidine-carboxylic acid monohydrate], a new antithrombin agent, on crescentic-type anti-GMB nephritis in rats].
Suzuki Y; Yamada H; Ito M
Nihon Jinzo Gakkai Shi; 1984 Apr; 26(4):463-73. PubMed ID: 6471586
[No Abstract] [Full Text] [Related]
12. Enzyme-controlling medicines: introduction.
Okamoto S; Hijikata-Okunomiya A; Wanaka K; Okada Y; Okamoto U
Semin Thromb Hemost; 1997; 23(6):493-501. PubMed ID: 9469621
[TBL] [Abstract][Full Text] [Related]
13. Stereoisomers of ketoconazole: preparation and biological activity.
Rotstein DM; Kertesz DJ; Walker KA; Swinney DC
J Med Chem; 1992 Jul; 35(15):2818-25. PubMed ID: 1495014
[TBL] [Abstract][Full Text] [Related]
14. Role of thrombin and thromboxane A2 in reocclusion following coronary thrombolysis with tissue-type plasminogen activator.
Fitzgerald DJ; Fitzgerald GA
Proc Natl Acad Sci U S A; 1989 Oct; 86(19):7585-9. PubMed ID: 2508092
[TBL] [Abstract][Full Text] [Related]
15. Thrombin inhibitors. 2. Amide derivatives of N alpha-substituted L-arginine.
Kikumoto R; Tamao Y; Ohkubo K; Tezuka T; Tonomura S; Okamoto S; Funahara Y; Hijikata A
J Med Chem; 1980 Aug; 23(8):830-6. PubMed ID: 7401110
[TBL] [Abstract][Full Text] [Related]
16. Effect of argatroban, a selective thrombin inhibitor, on animal models of cerebral thrombosis.
Tamao Y; Kikumoto R
Semin Thromb Hemost; 1997; 23(6):523-30. PubMed ID: 9469624
[TBL] [Abstract][Full Text] [Related]
17. Selection of S18326 as a new potent and selective boronic acid direct thrombin inhibitor.
Rupin A; Mennecier P; Lila C; de Nanteuil G; Verbeuren TJ
Thromb Haemost; 1997 Oct; 78(4):1221-7. PubMed ID: 9364988
[TBL] [Abstract][Full Text] [Related]
18. The antithrombotic effect of low molecular weight synthetic thrombin inhibitors, argatroban and PPACK, on He-Ne laser-induced thrombosis in rat mesenteric microvessels.
Yamashita T; Yamamoto J; Sasaki Y; Matsuoka A
Thromb Res; 1993 Jan; 69(1):93-100. PubMed ID: 8465278
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and pharmacological activity of 4-amino-5-chloro-2-methoxy-N-[(2S,4S)-1-ethyl-2-hydroxymethyl-4- pyrrolidinyl]benzamide (TKS159) and its optical isomers.
Yanagi T; Kitajima A; Anzai K; Kodama K; Mizoguchi J; Fujiwara H; Sakiyama H; Kamoda O; Kamei C
Chem Pharm Bull (Tokyo); 1999 Nov; 47(11):1650-4. PubMed ID: 10605060
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
